Cargando…

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia

B-cell receptor signaling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia. The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhibitor that may be better tolerated by patients who are int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409022/ https://www.ncbi.nlm.nih.gov/pubmed/33730844 http://dx.doi.org/10.3324/haematol.2020.272500

Ejemplares similares

Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
por: Izutsu, Koji, et al.
Publicado: (2021)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
por: Ghia, Paolo, et al.
Publicado: (2022)

A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
por: Strati, Paolo, et al.
Publicado: (2022)

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY
por: Owen, R., et al.
Publicado: (2022)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021)

P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
por: Skarbnik, Alan, et al.
Publicado: (2023)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL
por: Strati, P., et al.
Publicado: (2022)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
por: Yang, Shenmiao, et al.
Publicado: (2023)

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies
por: Edlund, Helena, et al.
Publicado: (2021)

P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS
por: Ghia, Paolo, et al.
Publicado: (2023)

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
por: Oyama, Takashi, et al.
Publicado: (2023)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
por: Phillips, Tycel, et al.
Publicado: (2023)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
por: Vreman, Rick A., et al.
Publicado: (2019)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
por: Roschewski, Mark, et al.
Publicado: (2023)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Teglgaard, Rebecca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ai6t0g28fptgsv0nr6ebl02lpd